A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors.

Trial Profile

A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs BI 836880 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 22 Feb 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 22 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 02 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top